KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Total Debt: 2020-2025

Historic Total Debt for AbCellera Biologics (ABCL) over the last 4 years, with Mar 2025 value amounting to $8.8 million.

  • AbCellera Biologics' Total Debt fell 82.95% to $8.8 million in Q1 2025 from the same period last year, while for Mar 2025 it was $8.8 million, marking a year-over-year decrease of 82.95%. This contributed to the annual value of $8.1 million for FY2024, which is 83.98% down from last year.
  • According to the latest figures from Q1 2025, AbCellera Biologics' Total Debt is $8.8 million, which was up 8.46% from $8.1 million recorded in Q4 2024.
  • AbCellera Biologics' 5-year Total Debt high stood at $54.9 million for Q2 2023, and its period low was $8.1 million during Q4 2024.
  • Moreover, its 3-year median value for Total Debt was $42.9 million (2023), whereas its average is $34.5 million.
  • As far as peak fluctuations go, AbCellera Biologics' Total Debt skyrocketed by 195.99% in 2022, and later tumbled by 83.98% in 2024.
  • Quarterly analysis of 5 years shows AbCellera Biologics' Total Debt stood at $22.9 million in 2021, then skyrocketed by 92.77% to $44.2 million in 2022, then rose by 14.17% to $50.5 million in 2023, then crashed by 83.98% to $8.1 million in 2024, then slumped by 82.95% to $8.8 million in 2025.
  • Its Total Debt was $8.8 million in Q1 2025, compared to $8.1 million in Q4 2024 and $20.2 million in Q3 2024.